A Study of IBI363 in Combination With Bevacizumab or Furuitinib in Subjects With Advanced Colorectal Cancer

Sponsor
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Study ID
NCT06717880
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Advanced Malignancies

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • IBI363 combined with Bevacizumab — DRUG
    IBI363 will be administrated on Day 1 of every 2 weeks or every 3 weeks, intravenous injection. Bevacizumab, intravenous injection.
  • IBI363 + Furuitinib — DRUG
    IBI363 Q2W or Q3W IV，Furuitinib po

Study Details

A Phase 1 study of IBI363 in combination with Bevacizumab or Furuitinib in Subjects with Advanced Colorectal Cancer

Key Dates

First listed
Dec 5, 2024
Start date
Jul 28, 2023
Status verified
Dec 2024
Primary completion
Jul 31, 2025
Completion
Jul 31, 2026

Study Design

Enrollment
260 participants (estimated)
Allocation
NA
Intervention model
FACTORIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Cohort A
    IBI363 Combined with Bevacizumab in Subjects with Advanced Colorectal Cancer
  • Experimental: Cohort B
    IBI363 Combined with Furuitinib in Subjects with Advanced Colorectal Cancer

Primary Outcome Measure

Adverse Event (AE), Treatment-Emergent AE (TEAE), Adverse Event of Special Interest (AESI) and Serious Adverse Event (SAE) [ Time Frame: Through out the study (up to 2 years) ]

Central Contacts

Related Studies